Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Overview of attention for article published in EJNMMI Research, September 2014

Altmetric Badge

About this Attention Score

Among the highest-scoring outputs from this source (#50 of 191)
Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 1 tweeter

facebook: 1 Facebook page

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 17 Mendeley

Summary Twitter Facebook Dimensions citations

So far, Dimensions has found 11 publications that cite this research output.

11

The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.

Combined medical therapy, nuclear medicine therapy and other therapies in metastatic neuroendocrine tumor

Book chapter (January 2022)

Peptide radiopharmaceuticals for targeted diagnosis & therapy of human tumors

Book chapter (January 2022)

ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy

Article in Journal of the ICRU (December 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.